CG-Luxidase

CG-Luxidase
Product Description

CG-Luxidase is a proprietary peptide-based delivery platform designed to enhance the penetration and distribution of active compounds by transiently modulating the hyaluronic acid (HA) network within the extracellular matrix (ECM).

As a water-soluble synthetic decapeptide (INCI: Decapeptide-51), CG-Luxidase temporarily loosens the HA structure, reducing diffusion resistance and enabling significantly improved tissue permeability. This mechanism facilitates the efficient delivery of peptides, proteins, and other bioactive molecules into target tissues.

Unlike conventional penetration enhancers, CG-Luxidase works through a controlled and reversible ECM modulation process, supporting enhanced delivery without compromising structural integrity.

Read more Show less

Caregen Co.,Ltd.

  • Country/Region:
    Korea, Republic Of
  • Founded:
    2001
  • On CPHI since:
    2016
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Biopharmaceutical company
Consumer Goods
Distributor/Import Export
Drug delivery device Supplier/Manufacturer
Manufacturer/Innovator
OTC
Other
Primary activities
API Producer
Biopharmaceutical
Cosmeceuticals
Cosmetic Ingredients
Nutraceuticals
OTC
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Details
    Specifications
    • Product Name: CG-Luxidase
    • INCI Name: Decapeptide-51
    • Product Type: Peptide-Based Delivery Platform
    • Peptide Type: Water-Soluble Synthetic Decapeptide
    • Mechanism of Action: Extracellular Matrix (ECM) Modulation
    • Function: Hyaluronic Acid (HA) Network Modulation
    • Application Type: Delivery Enhancement Technology
    Application Areas
    • Dermal Delivery Enhancement
    • Cosmetic Formulations
    • Skin HydrationPore Care
    • Wrinkle CareAnti-Aging
    • Transdermal Delivery
    • Localized Drug Delivery
    • Peptide Delivery
    • Protein Delivery
  • Selling Points
    Clinical Results Summary

    A total of three independent clinical studies involving 77 subjects were conducted to evaluate the performance of a CG-PTX facial mask powered by CG-Luxidase delivery technology.

    Participants applied the mask for 20 minutes daily, with visible improvements observed from Day 1 and significant enhancements across all key skin parameters within just 7 days.

    By Day 7, pore area was reduced by 53.11%, pore volume by 34.67%, pore depth by 28.7%, and pore count by 42.12%. Sebum levels decreased by 75.91%, delivering visibly refined pores and smoother skin texture.

    Skin hydration increased by 140.3%, indicating intense moisturizing and barrier-enhancing effects. In addition, wrinkle depth decreased by 69.40%, demonstrating powerful anti-aging benefits.
More specifications Fewer specifications

Caregen Co.,Ltd.

  • Country/Region:
    Korea, Republic Of
  • Founded:
    2001
  • On CPHI since:
    2016
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Biopharmaceutical company
Consumer Goods
Distributor/Import Export
Drug delivery device Supplier/Manufacturer
Manufacturer/Innovator
OTC
Other
Primary activities
API Producer
Biopharmaceutical
Cosmeceuticals
Cosmetic Ingredients
Nutraceuticals
OTC
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Caregen Co.,Ltd. (5)

  • CG-P5

    Product CG-P5

    First-in-Class VEGFR2-Inhibiting Peptide Eye Drop for Wet Age-Related Macular Degeneration

    Product Overview: A New Standard for Non-Invasive Retinal Therapy
    CG-P5 is a first-in-class VEGFR2-inhibiting biomimetic peptide developed as a topical eye drop for the treatment of wet age-related m...
  • CG-T1

    Product CG-T1

    Peptide-Based Topical Therapeutic for Dry Eye Disease (DED)

    Product Overview: A Restorative Approach to Dry Eye Disease

    CG-T1 is a next-generation peptide-based topical therapy for dry eye disease, advancing toward Phase 2 clinical development in the United States following successfu...
  • Korglutide

    Product Korglutide

    Korglutide is a next-generation oral dual GLP-1R/IGF-1R peptide designed to support safe and muscle-preserving weight loss as a non-injectable nutraceutical alternative.
    Product Overview
    Korglutide is a synthetic dual GLP-1R and IGF-1R agonist peptide developed by Caregen for weight management and ...
  • MyoKi

    Product MyoKi

    MyoKi is an oral anti-myostatin peptide designed to support muscle mass and strength, enabling safe and effective muscle health management across all age groups.

    Product OverviewMyoKi is a peptide-based nutraceutical developed to support muscle preservation and functional performance t...
  • ProGsterol

    Product ProGsterol

    ProGsterol is an oral peptide-based nutraceutical designed to improve insulin receptor sensitivity and regulate glucose metabolism, supporting overall metabolic balance.
    Product Overview
    ProGsterol is a peptide-based nutraceutical developed by Caregen for metabolic disorders, including insulin re...

Caregen Co.,Ltd. resources (1)